Filing Flows › Longeveron (LGVN) › Q1 2026 › vs Q1 2025
Longeveron (LGVN) Q1 2026 vs Q1 2025 (year over year)
Longeveron's revenue rose $17K (+4%) from $381K in Q1 2025 to $398K in Q1 2026. The biggest changes: Clinical Trial Revenue +$119K (+46%); Contract Manufacturing Revenue −$96K (-83%).
Longeveron, Q1 2026: revenue $398K (+4% year over year), net loss $4.7M, operating cash flow −$4.4M. The chart draws each line against Q1 2025, the increases inside each band.
Every line
| Line | Q1 2026 | Q1 2025 | Change | % |
|---|---|---|---|---|
| Clinical Trial Revenue | $378K | $259K | $119K | +46% |
| Contract Manufacturing Revenue | $20K | $116K | −$96K | -83% |
| Revenue | $398K | $381K | $17K | +4% |
| Other income, net | $39K | $170K | −$131K | -77% |
| Net loss | $4.7M | $5.0M | −$275K | -5% |
| Costs & expenses | $5.2M | $5.6M | −$389K | -7% |
| Operating costs | $5.2M | $5.6M | −$389K | -7% |
| Cost of revenue | $134K | $106K | $28K | +26% |
| Research & development | $2.3M | $2.5M | −$196K | -8% |
| General & admin | $2.7M | $2.9M | −$221K | -8% |
| Operating cash sources | $5.0M | $5.5M | −$457K | -8% |
| Depreciation & amortization | $252K | $421K | −$169K | -40% |
| Share-based compensation | $379K | $340K | $39K | +11% |
| Cash used in operations | $4.4M | $4.7M | −$327K | -7% |
| Net loss absorbed | $4.7M | $5.0M | −$275K | -5% |
| Working capital & other | $265K | $447K | −$182K | -41% |
Questions
How much did Longeveron's revenue grow year over year in Q1 2026?
Longeveron's revenue rose $17K (+4%) from $381K in Q1 2025 to $398K in Q1 2026.
What drove Longeveron's revenue change in Q1 2026?
Clinical Trial Revenue +$119K (+46%); Contract Manufacturing Revenue −$96K (-83%).